BEIJING: China’s vaccine specialist CanSino Biologics Inc. has won a Beijing patent approval for its
COVID-19 vaccine candidate Ad5-nCOV, reported by state media, citing documents from the country’s
intellectual-property regulatory authority.
It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People’s Daily reported on Sunday. The paper cited documents released by the National Intellectual Property Administration of China stating the patent was granted on 11 August.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino’s Hong Kong shares rose around 14% in Monday’s morning session. Its Shanghai shares rose by 6.6% as of midday.
